{"title":"Immediate hemodynamic stabilization with positive airway pressure: PTT-derived nocturnal blood pressure fluctuations during split-night polysomnography.","authors":"Deepesh Vaidya, Archita Joshi, Saumy Johnson","doi":"10.1007/s11325-026-03812-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>To evaluate the immediate hemodynamic effect of positive airway pressure (PAP) therapy on pulse transit time (PTT)-derived nocturnal blood pressure fluctuation (NBPF) during split-night polysomnography and to determine whether this effect differs between hypertensive and non-hypertensive individuals.</p><p><strong>Methods: </strong>This retrospective cohort study included 464 adults undergoing split-night polysomnography between 2015 and 2023. NBPF was defined as the standard deviation of systolic blood pressure (SBP) derived from PTT calibrated using manufacturer-validated algorithms. Within-group changes were assessed using paired t-tests, between-group comparisons used independent t-tests, and multivariable linear regression adjusted for age and baseline NBPF. Effect sizes (Cohen's d) and 95% confidence intervals (CI) were calculated.</p><p><strong>Results: </strong>NBPF decreased significantly after PAP therapy in both hypertensive (mean reduction 20.71 ± 24.25 mmHg, p < 0.001) and non-hypertensive groups (18.97 ± 23.58 mmHg, p < 0.001). Effect sizes were large (Cohen's d = 0.96 and 0.90, respectively). The adjusted between-group difference in NBPF reduction was not significant (β = 1.42 mmHg; 95% CI - 3.21 to 6.05; p = 0.54).</p><p><strong>Conclusions: </strong>PAP therapy during split-night studies produces immediate hemodynamic stabilization, reflected by a large and significant reduction in nocturnal BP variability in both hypertensive and non-hypertensive patients. These findings support early PAP initiation to mitigate nocturnal BP lability regardless of baseline hypertension status.</p>","PeriodicalId":520777,"journal":{"name":"Sleep & breathing = Schlaf & Atmung","volume":"30 5","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep & breathing = Schlaf & Atmung","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11325-026-03812-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Study objectives: To evaluate the immediate hemodynamic effect of positive airway pressure (PAP) therapy on pulse transit time (PTT)-derived nocturnal blood pressure fluctuation (NBPF) during split-night polysomnography and to determine whether this effect differs between hypertensive and non-hypertensive individuals.
Methods: This retrospective cohort study included 464 adults undergoing split-night polysomnography between 2015 and 2023. NBPF was defined as the standard deviation of systolic blood pressure (SBP) derived from PTT calibrated using manufacturer-validated algorithms. Within-group changes were assessed using paired t-tests, between-group comparisons used independent t-tests, and multivariable linear regression adjusted for age and baseline NBPF. Effect sizes (Cohen's d) and 95% confidence intervals (CI) were calculated.
Results: NBPF decreased significantly after PAP therapy in both hypertensive (mean reduction 20.71 ± 24.25 mmHg, p < 0.001) and non-hypertensive groups (18.97 ± 23.58 mmHg, p < 0.001). Effect sizes were large (Cohen's d = 0.96 and 0.90, respectively). The adjusted between-group difference in NBPF reduction was not significant (β = 1.42 mmHg; 95% CI - 3.21 to 6.05; p = 0.54).
Conclusions: PAP therapy during split-night studies produces immediate hemodynamic stabilization, reflected by a large and significant reduction in nocturnal BP variability in both hypertensive and non-hypertensive patients. These findings support early PAP initiation to mitigate nocturnal BP lability regardless of baseline hypertension status.